Biotech Values

[DewDiligence]

Addendum re Laurate FoB announcement:

Teva has a contract-manufacturing deal with Lonza (#msg-34930012), and MYL has a similar arrangement with Biocon (#msg-39119393), so we may presume that Laureate’s client is someone else.

Although Teva’s FoB deal with Lonza is non-exclusive, I think the statement above (from #msg-65525107) holds because Laureate does not have any FoB capabilities that Lonza lacks, and hence it’s unlikely that Teva would engage Laureate to manufacture one of Teva’s own FoB’s. (The non-exclusivity provision in the Teva-Lonza deal does, however, allow Teva to ink deals similar to the one Teva struck with ItalFarmaco many years ago to supply a knockoff of Lovenox.)

MYL’s deal with Biocon is exclusive for a wide array of FoB’s, and Biocon’s role in the deal is that of a full-fledged partner rather than just a contract manufacturer, so we can be reasonably confident that MYL is not working on FoB’s with Laureate.

Since Laureate’s PR says that Laureate’s client is “a leading generic pharmaceutical company” and Teva and MYL have been ruled out, there are very few companies who fit Laureate’s description of its client. That’s what makes this an intriguing development.